VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.40. This…
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.40. This…
November 07, 2024
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing PALISADE-3 and PALISADE-4 Phase 3 trials initiated and underway SOUTH…
November 07, 2024
Bionomics to Present at the 2024 CNS Summit
ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class,…
November 07, 2024
Bionomics to Present at the 2024 CNS Summit
ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class,…
November 07, 2024
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
On Target for Mid-2025 New Drug Application (NDA) Submission of lead ADHD asset CTx-1301 KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) — Cingulate Inc….
November 07, 2024
Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising …
Total Revenue (Q3 2024): $47.7 million, a 23% increase compared to Q3 2023. Fanapt Net Product Sales (Q3 2024): $23.9 million, a 12% increase compared…
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to loss…
November 06, 2024
Acadia: Q3 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported third-quarter net income of $32.8 million, after reporting a loss…
November 06, 2024
Vanda: Q3 Earnings Snapshot
WASHINGTON (AP) — WASHINGTON (AP) — Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported a loss of $5.3 million in its third quarter. The Washington-based company…
November 06, 2024
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
– 3Q24 NUPLAZID® (pimavanserin) net product sales of $159.2 million, up 10% year-over-year – 3Q24 DAYBUE™ (trofinetide) net product sales of $91.2 million, up 36%…
November 06, 2024
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024
CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that…